Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Monoclonal antibody combinations in ALL

Francesco Lanza, MD, Ravenna Hospital, Ravenna, Italy, outlines the sequential use of novel monoclonal antibodies for the treatment of adult acute lymphoblastic leukemia (ALL) who are relapsed/refractory to chemotherapy, including blinatumomab, a CD19 targeting monoclonal antibody, as well as inotuzumab ozogamicin, an antibody-drug conjugate. Dr Lanza also discusses the sequential use of CAR T-cell based therapies in combination with monoclonal antibodies and controversy surrounding this treatment approach. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).